Journal article
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study
American journal of hematology, Vol.100(4), pp.606-615
04/2025
DOI: 10.1002/ajh.27630
PMCID: PMC12489985
PMID: 39918101
Abstract
Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high-grade B cell lymphoma treated with R-GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy (n = 100), those utilizing R-GemOx as a bridge to ASCT or CAR T (n = 83), and those aged 70 and older (n = 71). Overall response rates (ORRs) for all patients treated with R-GemOx were 45% with a complete response (CR) rate of 29%. The median event-free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R-GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R-GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R-GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R-GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Details
- Title: Subtitle
- Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study
- Creators
- Samuel Yamshon - Weill Cornell MedicineJean L Koff - Emory UniversityMelissa C Larson - Mayo Clinic in FloridaBrad S Kahl - Washington University in St. LouisCarla Casulo - University of RochesterIzidore S Lossos - Sylvester Comprehensive Cancer CenterSara Haddadi - University of MiamiMichele Stanchina - Sylvester Comprehensive Cancer CenterDai Chihara - The University of Texas MD Anderson Cancer CenterAmy Ayers - The University of Texas MD Anderson Cancer CenterThomas M Habermann - Mayo ClinicYucai Wang - Mayo ClinicArushi Khurana - Mayo ClinicGrzegorz S Nowakowski - Mayo ClinicTanner W Reicks - Mayo Clinic in FloridaUmar Farooq - University of IowaBrian K Link - University of IowaJonathon B Cohen - Emory UniversityPeter Martin - Cornell UniversityJia Li - GenentechAshwini Shewade - GenentechConnie Lee Batlevi - GenentechAndrea Lo-Rossi - GenentechDavid Fox - GenentechAnthony Masaquel - GenentechYong Mun - GenentechJames R Cerhan - Mayo Clinic in FloridaChristopher R Flowers - The University of Texas MD Anderson Cancer CenterMatthew J Maurer - Mayo ClinicLoretta J Nastoupil - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- American journal of hematology, Vol.100(4), pp.606-615
- DOI
- 10.1002/ajh.27630
- PMID
- 39918101
- PMCID
- PMC12489985
- NLM abbreviation
- Am J Hematol
- ISSN
- 1096-8652
- eISSN
- 1096-8652
- Publisher
- WILEY
- Grant note
- U01 CA195568 / NIH HHS Genentech P50 CA097274 / NIH HHS
- Language
- English
- Electronic publication date
- 02/07/2025
- Date published
- 04/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984786280202771
Metrics
4 Record Views